Genmab — Januar 2018
-
-
Th1/17 hybrid T cells offer potent and durable anti-tumor response in preclinical model
Adoptive cell therapy for cancer involves harvesting T cells from a patient and expanding and sometimes modifying them in the laboratory before reinfusion. It has been challenging to create T cells that are both potent and durable. In a new study, researchers report the potent anti-tumor properties of hybrid Th1/Th17 cells that combine the cancer-fighting properties of Th1 cells and the ability of Th17 cells to self-renew and regenerate.
ScienceDaily (www.sciencedaily.com)
-
"We've known about NAD+ for almost 100 years, so, for me, the best part was when we realized that this intrinsic factor was responsible for the cells' strength," says Mehrotra. "That we could pick out one molecule, CD38, and produce this robust anti-tumor phenotype just by knocking it down was a big surprise. I actually thought that it wouldn't work-that we wouldn't get robust tumor control with the CD38 knockout cells. But it turns out that its ability to regulate the important cofactor NAD+ is
-
I hvert fald vil der være et problem med ventetiden. Ved ACT udtager man T-celler og kultiverer dem i uger eller mdr. Og i mellemtiden dør så patienten. Skeptikere ved car-t har netop peget på dette problem ved t-celle transplantationer i det hele taget.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind